Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

3(37.5%)

Phase 1

2(25.0%)

Phase 3

2(25.0%)

Phase 4

1(12.5%)

8Total

Phase 2(3)

Phase 1(2)

Phase 3(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07325227Phase 4Not Yet Recruiting

Study of Remimazolam for Cataract Surgery

Role: collaborator

NCT05776004Phase 2Active Not Recruiting

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

Role: lead

NCT02513095Phase 2Completed

Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)

Role: lead

NCT02162888Phase 1Completed

A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients

Role: lead

NCT03324061Phase 1Completed

Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration

Role: lead

NCT03600376Phase 3Completed

Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS

Role: lead

NCT03189433Phase 2Terminated

Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)

Role: lead

NCT01045018Phase 3Completed

A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis

Role: collaborator

All 8 trials loaded